title: Effect of a prolonged-release formulation of N-methionyl bovine somatotropin (sometribove) on milk fat.
abstract: Nine Holstein cows were injected bi-weekly with a prolonged-release formulation of N-methionyl bST, and 9 cows were injected with excipient. Intramuscular injections began at 60 +/- 3 d postpartum and continued at 14-d intervals for the full lactation. Administration of bST increased production of milk, total fat, and all milk fat components measured. Average fatty acid composition of milk fat was not influenced by bST treatment. Stage of lactation had a large influence on production and percentage of individual fatty acids in milk fat from both bST-treated and control cows. The stage of lactation impact on the fatty acid composition of milk fat reflected changes in the relative contributions of body fat mobilization and de novo synthesis of milk fat components in response to changes in energy balance. Initiation of bST treatment caused some transient changes in milk fatty acid composition that were related to energy balance. These changes were small compared with the normal changes because of stage of lactation in all cows. Phospholipid and cholesterol content of milk also changed with stage of lactation but were not influenced by bST treatment. Melting properties of milk fat were influenced greatly by stage of lactation. Bovine somatotropin did not cause any changes in composition or physical properties of milk fat that were outside the range of normal variation.
authors.affiliation: Department of Food Science, Cornell University, Ithaca, NY 14853.
authors.forename: J M
authors.initials: JM
authors.lastname: Lynch
authors.forename: D M
authors.initials: DM
authors.lastname: Barbano
authors.forename: D E
authors.initials: DE
authors.lastname: Bauman
authors.forename: G F
authors.initials: GF
authors.lastname: Hartnell
authors.forename: M A
authors.initials: MA
authors.lastname: Nemeth
mesh_terms: D000818:Animals; D002417:Cattle / Q000502:physiology*; D002784:Cholesterol / Q000032:analysis; D003692:Delayed-Action Preparations; D005227:Fatty Acids / Q000032:analysis; D005260:Female; D013006:Growth Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D006728:Hormones / Q000008:administration & dosage / Q000494:pharmacology; D006358:Hot Temperature; D019382:Human Growth Hormone; D007273:Injections, Intramuscular / Q000662:veterinary; D007774:Lactation / Q000187:drug effects*; D008055:Lipids / Q000032:analysis* / Q000096:biosynthesis / Q000737:chemistry; D008892:Milk / Q000032:analysis / Q000187:drug effects*; D010743:Phospholipids / Q000032:analysis; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D003692:Delayed-Action Preparations; D005227:Fatty Acids; D006728:Hormones; D008055:Lipids; D010743:Phospholipids; D011994:Recombinant Proteins; D019382:Human Growth Hormone; D013006:Growth Hormone; D002784:Cholesterol